Patients' clinical characteristics
. | All patients . | IgVH patients only . | Previously untreated only . |
|---|---|---|---|
| No. patients | 127 | 67 | 85 |
| Age, y, median (range) | 61 (33-83) | 61 (33-83) | 59 (33-80) |
| Male, no. (%) | 75 (59) | 38 (56) | 48 (56) |
| WBC, × 109/L, median (range) | 47.5 (2-233.9) | 49.2 (2.4-233.9) | 48 (3.9-233.9) |
| Lymphocytes, % (range) | 82 (9-97) | 84 (17-97) | 85 (17-97) |
| Platelets, × 109/L (range) | 147 (7-342) | 149 (7-342) | 164 (45-342) |
| Hemoglobin, g/L (range) | 12.8 (6.2-17.8) | 12.6 (6.4-15.7) | 13.2 (9.4-16.3) |
| β2-M, mg/L | 3.4 (1.3-17.7) | 3.4 (1.3-11.7) | 2.8 (1.3-8.8) |
| Bone marrow cellularity, % (range) | 50 (10-95) | 47 (10-95) | 50 (15-95) |
| Bone marrow lymphocyte, % (range) | 61 (4-95) | 67 (12-95) | 64 (4-95) |
| Rai stage, no. (%) | |||
| 0 | 27 (21) | 15 (22) | 24 (28) |
| I | 40 (31) | 18 (27) | 30 (35) |
| II | 25 (20) | 13 (19) | 17 (20) |
| III | 7 (6) | 4 (6) | 3 (4) |
| IV | 28 (22) | 15 (23) | 11 (13) |
| Binet stage, no. (%) | |||
| A | 59 (46) | 31 (47) | 48 (57) |
| B | 34 (27) | 17 (26) | 22 (26) |
| C | 34 (27) | 18 (27) | 14 (16) |
| Lymph nodes involved, no. (%) | |||
| 0 to 1 | 58 (46) | 31 (47) | 43 (51) |
| 2 to 3 or more | 69 (54) | 36 (53) | 42 (49) |
| Previously treated, no. (%) | 42 (33) | 20 (30) | NA |
| Hepatomegaly, no. (%) | 24 (19) | 10 (15) | 9 (11) |
| Splenomegaly, no. (%) | 46 (36) | 21 (32) | 18 (21) |
. | All patients . | IgVH patients only . | Previously untreated only . |
|---|---|---|---|
| No. patients | 127 | 67 | 85 |
| Age, y, median (range) | 61 (33-83) | 61 (33-83) | 59 (33-80) |
| Male, no. (%) | 75 (59) | 38 (56) | 48 (56) |
| WBC, × 109/L, median (range) | 47.5 (2-233.9) | 49.2 (2.4-233.9) | 48 (3.9-233.9) |
| Lymphocytes, % (range) | 82 (9-97) | 84 (17-97) | 85 (17-97) |
| Platelets, × 109/L (range) | 147 (7-342) | 149 (7-342) | 164 (45-342) |
| Hemoglobin, g/L (range) | 12.8 (6.2-17.8) | 12.6 (6.4-15.7) | 13.2 (9.4-16.3) |
| β2-M, mg/L | 3.4 (1.3-17.7) | 3.4 (1.3-11.7) | 2.8 (1.3-8.8) |
| Bone marrow cellularity, % (range) | 50 (10-95) | 47 (10-95) | 50 (15-95) |
| Bone marrow lymphocyte, % (range) | 61 (4-95) | 67 (12-95) | 64 (4-95) |
| Rai stage, no. (%) | |||
| 0 | 27 (21) | 15 (22) | 24 (28) |
| I | 40 (31) | 18 (27) | 30 (35) |
| II | 25 (20) | 13 (19) | 17 (20) |
| III | 7 (6) | 4 (6) | 3 (4) |
| IV | 28 (22) | 15 (23) | 11 (13) |
| Binet stage, no. (%) | |||
| A | 59 (46) | 31 (47) | 48 (57) |
| B | 34 (27) | 17 (26) | 22 (26) |
| C | 34 (27) | 18 (27) | 14 (16) |
| Lymph nodes involved, no. (%) | |||
| 0 to 1 | 58 (46) | 31 (47) | 43 (51) |
| 2 to 3 or more | 69 (54) | 36 (53) | 42 (49) |
| Previously treated, no. (%) | 42 (33) | 20 (30) | NA |
| Hepatomegaly, no. (%) | 24 (19) | 10 (15) | 9 (11) |
| Splenomegaly, no. (%) | 46 (36) | 21 (32) | 18 (21) |
NA indicates not applicable.